GVH
MCID: GRF001
MIFTS: 52

Graft-Versus-Host Disease, Protection Against (GVH) malady

Categories: Genetic diseases, Blood diseases, Rare diseases

Aliases & Classifications for Graft-Versus-Host Disease, Protection Against

Aliases & Descriptions for Graft-Versus-Host Disease, Protection Against:

Name: Graft-Versus-Host Disease, Protection Against 54 38 13
Graft Versus Host Disease 38 56 29 52
Graft-Versus-Host Disease, Susceptibility to 54
Graft-Versus-Host Disease 52
Graft-Vs-Host Disease 69
Gvh 56

Characteristics:

Orphanet epidemiological data:

56
graft versus host disease
Inheritance: Not applicable; Prevalence: 1-9/100000 (Europe); Age of onset: All ages;

Classifications:

Orphanet: 56  
Rare immunological diseases


External Ids:

OMIM 54 614395
Orphanet 56 ORPHA39812
ICD10 via Orphanet 34 T86.0

Summaries for Graft-Versus-Host Disease, Protection Against

OMIM : 54 Transplantation of hematopoietic stem cells is a successful therapy for some tumors derived from bone marrow... (614395) more...

MalaCards based summary : Graft-Versus-Host Disease, Protection Against, also known as graft versus host disease, is related to chronic graft versus host disease and acute graft versus host disease. An important gene associated with Graft-Versus-Host Disease, Protection Against is IL10 (Interleukin 10), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Cyclosporine and Methotrexate have been mentioned in the context of this disorder. Affiliated tissues include Bone, bone and bone marrow, and related phenotypes are digestive/alimentary and hematopoietic system

Related Diseases for Graft-Versus-Host Disease, Protection Against

Diseases related to Graft-Versus-Host Disease, Protection Against via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 200)
id Related Disease Score Top Affiliating Genes
1 chronic graft versus host disease 12.7
2 acute graft versus host disease 12.6
3 hematopoietic stem cell transplantation 11.6
4 bronchiolitis obliterans 11.5
5 leukemia 10.6
6 clubfoot, congenital, with or without deficiency of long bones and/or mirror-image polydactyly 10.2 IL10 IL2
7 pyridoxal 5'-phosphate-dependent epilepsy 10.2 IL10 TNF
8 tungiasis 10.2 IFNG IL10
9 paralytic poliomyelitis 10.2 IFNG IL2
10 caplan's syndrome 10.2 IFNG IL2
11 tubular renal disease-cardiomyopathy syndrome 10.2 IL10 TNF
12 lagophthalmos 10.2 IL10 TNF
13 centronuclear myopathy 5 10.2 IFNG IL10
14 discharging ear 10.2 IFNG IL10
15 multiple vertebral anomalies unusual facies 10.2 IL10 TNF
16 conidiobolomycosis 10.2 IL10 TNF
17 steatitis 10.2 IL2 TNF
18 endosalpingiosis 10.2 IL10 TNF
19 multiple epiphyseal dysplasia due to collagen 9 anomaly 10.2 IFNG IL2
20 myofibroma 10.2 IFNG IL10
21 idiopathic hypertrophic pachymeningitis 10.2 IL10 TNF
22 lepromatous leprosy 10.2 IFNG IL10
23 transient tic disorder 10.2 IL10 TNF
24 vestibule of mouth cancer 10.2 IL10 TNF
25 tarsal tunnel syndrome 10.2 IL10 TNF
26 spastic paraplegia 19 10.2 IFNG IL2
27 rosacea 10.2 IFNG IL10
28 thymic neuroendocrine carcinoma 10.2 IL2 TNF
29 chronic apical periodontitis 10.2 IL10 TNF
30 elephantiasis 10.2 IFNG IL10
31 hemangioma of orbit 10.2 IL2 TNF
32 stocco dos santos syndrome 10.2 IFNG TNF
33 distal trisomy 14q 10.2 IFNG TNF
34 multiple mitochondrial dysfunctions syndrome 10.2 IFNG IL10
35 tinea capitis 10.2 IL2 TNF
36 aniseikonia 10.2 IFNG TNF
37 hypoparathyroidism-retardation-dysmorphism syndrome 10.2 IL10 TNF
38 urethral intrinsic sphincter deficiency 10.2 IFNG TNF
39 congenital hypothyroidism 10.2 IL10 TNF
40 sarcomatoid transitional cell carcinoma 10.1 IL10 TNF
41 mirizzi syndrome 10.1 KIR3DL1 TNF
42 trichomalacia 10.1 IL10 TNF
43 esophagus lymphoma 10.1 IFNG TNF
44 phlyctenulosis 10.1 IL10 TNF
45 hypotrichosis 4 10.1 IFNG TNF
46 spastic paraplegia 1 10.1 IFNG TNF
47 myeloid and lymphoid neoplasms with eosinophilia and abnormalities of pdgfra, pdgfrb, and fgfr1 10.1 IFNG TNF
48 gastric dilatation 10.1 IL10 TNF
49 rheumatoid factor-negative juvenile idiopathic arthritis without anti-nuclear antibodies 10.1 IL10 TNF
50 pseudo-meigs syndrome 10.1 IL10 TNF

Graphical network of the top 20 diseases related to Graft-Versus-Host Disease, Protection Against:



Diseases related to Graft-Versus-Host Disease, Protection Against

Symptoms & Phenotypes for Graft-Versus-Host Disease, Protection Against

Clinical features from OMIM:

614395

MGI Mouse Phenotypes related to Graft-Versus-Host Disease, Protection Against:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.88 IFNG IL10 IL2 IL2RA TNF TNFRSF4
2 hematopoietic system MP:0005397 9.85 IFNG IL10 IL2 IL2RA TNF TNFRSF4
3 immune system MP:0005387 9.8 IFNG IL10 IL2 IL2RA TNF TNFRSF4
4 liver/biliary system MP:0005370 9.65 IL10 IL2 TNF TNFRSF4 IFNG
5 neoplasm MP:0002006 9.46 IFNG IL10 IL2 TNF
6 respiratory system MP:0005388 9.43 IFNG IL10 IL2 IL2RA TNF TNFRSF4
7 vision/eye MP:0005391 9.02 IFNG IL10 IL2 IL2RA TNF

Drugs & Therapeutics for Graft-Versus-Host Disease, Protection Against

Drugs for Graft-Versus-Host Disease, Protection Against (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 440)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cyclosporine Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 79217-60-0, 59865-13-3 5284373 6435893
2
Methotrexate Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 1959-05-2, 59-05-2 126941
3
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 22916-47-8 4189
4
Tacrolimus Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 104987-11-3 445643 439492
5
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 159351-69-6 6442177
6
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 53123-88-9 5284616 6436030 46835353
7
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 53-03-2 5865
8
Cyclophosphamide Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
9
Lenograstim Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 135968-09-1
10
Thiotepa Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 52-24-4 5453
11
Basiliximab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 152923-56-3, 179045-86-4
12
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 128794-94-5 5281078
13
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 24280-93-1 446541
14
Busulfan Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 55-98-1 2478
15
Fludarabine Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 21679-14-1, 75607-67-9 30751
16
Cytarabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 147-94-4 6253
17
Vidarabine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 24356-66-9 32326 21704
18
Daclizumab Approved, Investigational Phase 4,Phase 3,Phase 2 152923-56-3
19
Infliximab Approved Phase 4,Phase 3,Phase 2,Phase 1 170277-31-3
20
Deferasirox Approved, Investigational Phase 4 201530-41-8 5493381
21
Iron Approved Phase 4,Phase 1 7439-89-6 23925
22
Posaconazole Approved, Investigational, Vet_approved Phase 4,Phase 3 171228-49-2 147912
23
Menthol Approved Phase 4,Phase 2,Phase 1 2216-51-5 16666
24
Peginterferon alfa-2b Approved Phase 4 99210-65-8, 215647-85-1
25
Itraconazole Approved, Investigational Phase 4 84625-61-6 55283
26
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 59-30-3 6037
27
leucovorin Approved, Nutraceutical Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 58-05-9 54575, 6560146 143
28 Antibodies Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
29 Antirheumatic Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
30 Dermatologic Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
31 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1
32 Immunoglobulins Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
33 Immunosuppressive Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
34 Antifungal Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
35 Anti-Infective Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
36 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
37 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
38 Calcineurin Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
39 Folic Acid Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
40 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
41 Vitamin B Complex Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
42 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
43 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
44 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1
45 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1
46 glucocorticoids Phase 4,Phase 2,Phase 3,Phase 1
47 Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1
48 Hormones Phase 4,Phase 2,Phase 3,Phase 1
49 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1
50 Alkylating Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 1285)
id Name Status NCT ID Phase
1 Anti Cytokine Combination Therapy With Daclizumab and Infliximab for Treatment of Steroid Refractory Acute GVHD Completed NCT00574470 Phase 4
2 Study to Assess the Safety and Efficacy of Tacrolimus (Prograf Capsule/Injection) and Methotrexate (MTX) Combination Therapy for Prevention of Graft Versus Host Disease (GVHD) in Patients Who Received Peripheral Hematopoietic Stem Cell Transplantation Fro Completed NCT02660684 Phase 4
3 Study Comparing Cyclosporine Dose Reduction vs. Cyclosporine Elimination in Kidney Transplant Recipients Taking Sirolimus Completed NCT00195468 Phase 4
4 Study Evaluating Sirolimus in Kidney Transplant Recipients in India Completed NCT00195481 Phase 4
5 A Study Comparing the Withdrawal of Steroids or Tacrolimus in Kidney Transplant Recipients Completed NCT00195429 Phase 4
6 Study Evaluating Sirolimus in End Stage Renal Disease in High Risk Kidney Transplant Recipients Completed NCT00044720 Phase 4
7 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4
8 Antifugal Effect of Recombinant Human Granulocyte-macrophage Stimulating Factor (rhGM-CSF) in Patients Post Allo-HSCT Completed NCT01232504 Phase 4
9 Open-Label Single-Arm Pilot Study in Adult Allogeneic Hematopoietic Stem Cell Transplant Recipients With Transfusional Iron Overload Completed NCT01335035 Phase 4
10 Efficacy of Basiliximab in the Prevention of Acute Graft-versus-host Disease in Unrelated Allogeneic Hematopoietic Stem Cell Transplantation Therapy for Thalassemia Major Recruiting NCT02342145 Phase 4
11 Anti-thymocyte Globulins for Graft-versus-host Disease Prophylaxis Recruiting NCT01856803 Phase 4
12 Peg Interferon α-2b for Relapsed Hematological Malignancies After Allo-HSCT Recruiting NCT02634294 Phase 4
13 Efficacy and Safety Study of ATG for Prophylaxis of aGVHD in Matched Sibling Donor PBSCT Recruiting NCT02677181 Phase 4
14 Pharmacokinetics of Posaconazole (Noxafil®) as Prophylaxis for Invasive Fungal Infections Recruiting NCT02805946 Phase 4
15 Post-transplantation Cyclophosphamide for Haploidentical Transplant From Maternal or Collateral Donors Recruiting NCT02412423 Phase 4
16 Efficacy and Safety of rHuTPO on Platelet Engraftment After Allo-HSCT Recruiting NCT01379391 Phase 4
17 Haploidentical Hematopoietic Stem Cell Transplantation for Patients With Thalassemia Major Recruiting NCT03171831 Phase 4
18 ALL SCTped FORUM - Pharmacogenomic Study (add-on Study) Recruiting NCT02670564 Phase 4
19 A Randomized Phase IV Control Trial of Single High Dose Oral Vitamin D3 in Pediatric Patients Undergoing HSCT Not yet recruiting NCT03176849 Phase 4
20 Study of Busulfan and FLAG Conditioning Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation Not yet recruiting NCT02784561 Phase 4
21 Evaluation of Antifungal Prophylaxis on Graft-versus-host Disease (GVHD) Patients Terminated NCT01282879 Phase 4
22 The Prophylactic Use of Topical Cyclosporine A 0.05% to Prevent Graft Versus Host Disease Related Dry Eye Terminated NCT00553735 Phase 4
23 Busulfan Pharmacokinetic Analysis and GST Polymorphism in Adults Undergoing Hematological Stem Cell Transplantation Withdrawn NCT01071486 Phase 4
24 Efficacy and Safety Study of Allogenic Mesenchymal Stem Cells for Patients With Chronic Graft Versus Host Disease Unknown status NCT01526850 Phase 2, Phase 3
25 Extracorporeal Photopheresis for Acute Graft Versus Host Disease Unknown status NCT00179855 Phase 2, Phase 3
26 Trial of Filgrastim Versus Placebo Following Allogeneic Bone Marrow Transplantation Unknown status NCT00207792 Phase 3
27 Thymoglobulin in Unrelated Hematopoietic Progenitor Cell Transplantation Unknown status NCT01217723 Phase 3
28 MSC and Cyclophosphamide for Acute Graft-Versus-Host Disease (aGVHD) Prophylaxis Unknown status NCT02270307 Phase 2, Phase 3
29 Randomized Study of ATG for Graft Versus Host Disease (GVHD) Prevention in Paediatric Patients Given an Unrelated Donor Stem Cell Transplantation Unknown status NCT00934557 Phase 3
30 Hematopoietic Stem Cell Transplantation for Mucopolysaccharidosis Unknown status NCT01238328 Phase 2, Phase 3
31 ALL-SCT BFM International- HSCT in Children and Adolescents With ALL Unknown status NCT01423500 Phase 3
32 Allogeneic Stem Cell Transplantation in Children and Adolescents With Acute Lymphoblastic Leukaemia Unknown status NCT01423747 Phase 3
33 Hematopoietic Stem Cell Transplantation for Malignant Infantile Osteopetrosis Unknown status NCT01087398 Phase 2, Phase 3
34 Comparison of Cy-Atg vs Flu-Atg for the Conditioning Therapy in Allo-HCT for Adult Aplastic Anemia Unknown status NCT01145976 Phase 3
35 Unrelated Double Umbilical Cord Blood Units Transplantation Unknown status NCT01015742 Phase 2, Phase 3
36 T-Cell Depletion and Stem Cell Transplant for Immune Deficiencies and Histiocytic Disorders Unknown status NCT00176826 Phase 2, Phase 3
37 Allogeneic Transplantation For Severe Osteopetrosis Unknown status NCT00775931 Phase 2, Phase 3
38 Tacrolimus/Methotrexate Versus Cyclosporine/Methotrexate for Prophylaxis of Graft Versus Host Disease Completed NCT01788501 Phase 2, Phase 3
39 Study Comparing ABX-CBL (Monoclonal Antibody) Versus Atgam in Patients With Steroid Resistant Acute Graft Versus Host Disease Completed NCT00035880 Phase 2, Phase 3
40 Clinical Trial With Clobetasol and Dexamethasone for Topical Treatment of Oral Lesions of Chronic Graft-versus-host Disease Completed NCT01699412 Phase 3
41 Acute Graft-versus-Host Disease Treatment (BMT CTN 0802) Completed NCT01002742 Phase 3
42 Beclomethasone Plus Prednisone in Treating Patients With Graft-Versus-Host Disease Completed NCT00043147 Phase 3
43 Hydroxychloroquine in Treating Patients With Newly Diagnosed Chronic Graft-Versus-Host Disease Completed NCT00031824 Phase 3
44 Methylprednisolone With or Without Daclizumab in Treating Patients With Acute Graft-Versus-Host Disease Completed NCT00053976 Phase 3
45 Efficacy and Safety Study of Budesonide to Treat Oral Chronic Graft vs Host Disease (cGvHD) Completed NCT00887263 Phase 3
46 Treatment of Gastro-Intestinal and/or Hepatic Graft Versus Host Disease With Budesonide in Patients Following Peripheral Blood Stem Cell Transplantation Completed NCT00128739 Phase 3
47 The Use of Etanercept Enbrel as Sole Treatment for Grade I Acute Graft Versus Host Disease Completed NCT00726375 Phase 3
48 Acute Graft-Versus-Host Disease (aGvHD) Prophylaxis With ATG-Fresenius in Matched Unrelated Donor-Stem Cell Transplantation (MUD-SCT) Completed NCT00655343 Phase 3
49 Low-Dose Prednisone or Methylprednisolone in Treating Patients With Newly Diagnosed Acute Graft-versus-Host Disease Completed NCT00929695 Phase 3
50 Randomized Study of Oral Beclomethasone Dipropionate With Ten Days of Prednisone for Treatment of Gastrointestinal GVHD Completed NCT00233896 Phase 3

Search NIH Clinical Center for Graft-Versus-Host Disease, Protection Against

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Genetic Tests for Graft-Versus-Host Disease, Protection Against

Genetic tests related to Graft-Versus-Host Disease, Protection Against:

id Genetic test Affiliating Genes
1 Graft-Versus-Host Disease, Susceptibility to 29

Anatomical Context for Graft-Versus-Host Disease, Protection Against

MalaCards organs/tissues related to Graft-Versus-Host Disease, Protection Against:

39
Bone, Bone Marrow, T Cells, Liver
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Graft-Versus-Host Disease, Protection Against:
id Tissue Anatomical CompartmentCell Relevance
1 Bone Bone Marrow Bone Marrow Stromal Cells Potential therapeutic candidate

Publications for Graft-Versus-Host Disease, Protection Against

Variations for Graft-Versus-Host Disease, Protection Against

Copy number variations for Graft-Versus-Host Disease, Protection Against from CNVD:

7
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 188553 4 66300000 70400000 Absence of gene UGT2B17 Graft versus host disease

Expression for Graft-Versus-Host Disease, Protection Against

Search GEO for disease gene expression data for Graft-Versus-Host Disease, Protection Against.

Pathways for Graft-Versus-Host Disease, Protection Against

Pathways related to Graft-Versus-Host Disease, Protection Against according to GeneCards Suite gene sharing:

(show top 50) (show all 52)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.8 IFNG IL10 IL2 IL2RA KIR3DL1 TNF
2
Show member pathways
13.46 IFNG IL10 IL2 IL2RA TNF TNFRSF4
3
Show member pathways
13.34 IFNG IL10 IL2 IL2RA TNF
4
Show member pathways
13.22 IL10 IL2 IL2RA TNF TNFRSF4
5
Show member pathways
13.19 IFNG IL10 IL2 IL2RA TNF TNFRSF4
6
Show member pathways
13.13 IL10 IL2 IL2RA TNF TNFRSF4
7
Show member pathways
12.75 IFNG IL10 IL2 TNF
8
Show member pathways
12.67 IFNG IL2 IL2RA TNF
9
Show member pathways
12.67 IFNG IL10 IL2 IL2RA KIR3DL1 TNF
10
Show member pathways
12.51 IFNG IL10 IL2 IL2RA TNF
11
Show member pathways
12.48 IFNG IL10 IL2 TNF
12
Show member pathways
12.47 IFNG IL10 IL2 IL2RA TNF
13
Show member pathways
12.42 IFNG IL2 KIR3DL1 TNF
14
Show member pathways
12.34 IFNG IL10 IL2 TNF
15 12.29 IFNG IL10 IL2 IL2RA TNF TNFRSF4
16 12.28 IL2 IL2RA TNF
17
Show member pathways
12.2 IFNG IL2 TNF
18
Show member pathways
12.14 IFNG IL10 TNF
19
Show member pathways
12.13 IFNG IL10 IL2 IL2RA
20 12.11 IFNG IL10 TNF
21
Show member pathways
12.08 IFNG IL10 IL2 TNF
22
Show member pathways
11.97 IFNG IL2 IL2RA
23 11.92 IFNG IL2 TNF
24
Show member pathways
11.88 IFNG IL2 IL2RA
25
Show member pathways
11.88 IFNG IL10 IL2 TNF
26 11.87 IFNG IL10 IL2 IL2RA TNF
27 11.8 IFNG IL10 TNF
28
Show member pathways
11.71 IFNG IL2 IL2RA TNF
29 11.69 IFNG IL10 IL2 TNF
30 11.64 IL10 IL2RA TNF TNFRSF4
31
Show member pathways
11.61 IFNG IL2 TNF
32 11.6 IFNG IL10 IL2 IL2RA
33 11.56 IFNG IL10 IL2 IL2RA TNF
34 11.51 IFNG IL2 TNF
35 11.48 IFNG IL10 TNF
36 11.47 IFNG IL2 TNF
37
Show member pathways
11.41 IFNG TNF
38 11.4 IL10 TNF
39 11.39 IFNG TNF
40 11.36 IFNG TNF
41
Show member pathways
11.34 IFNG IL2 IL2RA TNF TNFRSF4
42 11.32 IFNG IL10 TNF
43 11.28 IFNG IL2 IL2RA
44 11.24 IL10 TNF
45 11.21 IFNG IL10 IL2 TNF
46 11.2 IFNG TNF
47 11.2 IFNG IL2 IL2RA
48
Show member pathways
11.16 IFNG IL2RA
49 11.09 IL10 IL2 TNF
50 11.08 IFNG IL10 IL2 TNFRSF4

GO Terms for Graft-Versus-Host Disease, Protection Against

Cellular components related to Graft-Versus-Host Disease, Protection Against according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 8.8 IFNG IL2RA TNF

Biological processes related to Graft-Versus-Host Disease, Protection Against according to GeneCards Suite gene sharing:

(show all 39)
id Name GO ID Score Top Affiliating Genes
1 MAPK cascade GO:0000165 9.83 IL2 IL2RA TNF
2 inflammatory response GO:0006954 9.83 IL10 IL2RA TNF TNFRSF4
3 defense response to bacterium GO:0042742 9.81 IFNG IL10 TNF
4 positive regulation of protein phosphorylation GO:0001934 9.77 IFNG IL2 TNF
5 cellular response to lipopolysaccharide GO:0071222 9.73 IFNG IL10 TNF
6 positive regulation of cell adhesion GO:0045785 9.68 IFNG TNF
7 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.68 IFNG IL2
8 positive regulation of interferon-gamma production GO:0032729 9.67 IL2 TNF
9 positive regulation of nitric oxide biosynthetic process GO:0045429 9.67 IFNG TNF
10 extrinsic apoptotic signaling pathway GO:0097191 9.67 IFNG TNF
11 positive regulation of B cell proliferation GO:0030890 9.66 IL2 TNFRSF4
12 negative regulation of T cell proliferation GO:0042130 9.66 IL10 IL2RA
13 positive regulation of cytokine secretion GO:0050715 9.65 IL10 TNF
14 protein import into nucleus, translocation GO:0000060 9.65 IFNG TNF
15 negative regulation of inflammatory response GO:0050728 9.65 IL10 IL2 IL2RA
16 negative regulation of mitotic cell cycle GO:0045930 9.64 IL10 TNF
17 positive regulation of activated T cell proliferation GO:0042104 9.64 IL2 IL2RA
18 negative regulation of interleukin-6 production GO:0032715 9.63 IL10 TNF
19 positive regulation of protein complex assembly GO:0031334 9.62 IFNG TNF
20 positive regulation of osteoclast differentiation GO:0045672 9.62 IFNG TNF
21 defense response to protozoan GO:0042832 9.61 IFNG IL10
22 positive regulation of T cell differentiation GO:0045582 9.61 IL2 IL2RA
23 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.6 IL10 TNF
24 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.58 IFNG TNF
25 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.58 IL10 TNF
26 positive regulation of T cell proliferation GO:0042102 9.58 IFNG IL2 IL2RA
27 positive regulation of immunoglobulin secretion GO:0051024 9.57 IL2 TNFRSF4
28 positive regulation of chemokine biosynthetic process GO:0045080 9.55 IFNG TNF
29 positive regulation of isotype switching to IgG isotypes GO:0048304 9.54 IFNG IL2
30 endothelial cell apoptotic process GO:0072577 9.51 IL10 TNF
31 positive regulation of MHC class II biosynthetic process GO:0045348 9.49 IFNG IL10
32 negative regulation of cytokine secretion involved in immune response GO:0002740 9.46 IL10 TNF
33 negative regulation of lymphocyte proliferation GO:0050672 9.43 IL2 IL2RA
34 receptor biosynthetic process GO:0032800 9.37 IL10 TNF
35 regulation of T cell homeostatic proliferation GO:0046013 9.32 IL2 IL2RA
36 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.26 IFNG TNF
37 immune response GO:0006955 9.17 IFNG IL10 IL2 IL2RA KIR3DL1 TNF
38 positive regulation of vitamin D biosynthetic process GO:0060557 9.16 IFNG TNF
39 negative regulation of growth of symbiont in host GO:0044130 9.13 IFNG IL10 TNF

Molecular functions related to Graft-Versus-Host Disease, Protection Against according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 8.92 IFNG IL10 IL2 TNF

Sources for Graft-Versus-Host Disease, Protection Against

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....